Navigation Links
RNA aptamers targeted to plasminogen activator inhibitor
Date:6/19/2014

New Rochelle, NY, June 19, 2014Plasminogen activators are proteins involved in the breakdown of blood clots, and an elevated level of plasminogen activator inhibitor-1 (PAI-1) is associated with an increased risk for clotting and cardiovascular disease. No PAI-1 inhibitors are currently available for clinical use, but a novel therapeutic approach using a targeted RNA aptamer drug that has been shown to block PAI-1 activity and prevent PAI-1-associated vascular events is described in Nucleic Acid Therapeutics, a peer-reviewed journal from Nucleic Acid Therapeutics. The article is available free on the Nucleic Acid Therapeutics website.

Jared Damare, Stephanie Brandal, and Yolanda Fortenberry, Johns Hopkins University School of Medicine, Baltimore, MD, designed a library of small RNA molecules that target different regions of PAI-1. They then screened the library and enriched for the aptamers that were the most selective for binding to and inhibiting the function of PAI-1. The authors demonstrate the ability of these RNA aptamers to prevent PAI-1 from interacting with plasminogen activators in the article "Inhibition of PAI-1 Antiproteolytic Activity Against tPA by RNA Aptamers."

"Even beyond the admirable care and rigor of the work, the therapeutic significance lies in the authors addressing a vital concern: the identification of an aptamer that can specifically disrupt the target function of PAI-1 without inhibiting its other functions," says Executive Editor Graham C. Parker, PhD, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Children's Hospital of Michigan, Detroit, MI.

Nucleic Acid Therapeutics is under th
'/>"/>

Contact: Vicki Cohn
vcohn@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Single protein targeted as the root biological cause of several childhood psychiatric disorders
2. Tiny probes shine brightly to reveal the location of targeted tissues
3. 11th International Congress on Targeted Anticancer Therapies
4. Study opens new prospects for developing new targeted therapies for breast cancer
5. Protein targeted for cancer drug development is essential for normal heart function
6. With early, obvious benefit of a targeted cancer drug, should expensive clinical testing continue?
7. Targeted culling of deer controls disease with little effect on hunting
8. Researchers use nanoscale patches to sensitize targeted cell receptors
9. Fruit pest targeted by genomic research
10. Targeted treatment can significantly reduce relapse in children with AML leukemia
11. Targeted synthesis of natural products with light
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
RNA aptamers targeted to plasminogen activator inhibitor
(Date:4/10/2015)... 2015 Research and Markets ( ... "Security Competitive Profiles - NEC" report to their ... NEC will continue to supply a range of IT ... a company focus on the development of a Big ... opportunities in the Asia-Pacific region ...
(Date:4/6/2015)... , Apr. 6, 2015 NXT-ID, Inc. ... a biometric authentication company focused on the growing ... filed provisional patent 62/143028 for MINIATURE, ... ENERGY TRANSFER  NXT-ID introduces a new ... This patent surrounds the use of miniature antenna ...
(Date:4/2/2015)... According to preliminary estimates Fingerprint ... higher than 125 MSEK. This exceeds the guidance provided ... revenues for Q1 2015 would be in line with ... 2014. The operating result for the first quarter is ... report will as previously communicated be published on May ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Revises Revenues for Q1 2015 2
... and successful lab tests of "killer paper," a material ... that helps preserve foods by fighting the bacteria that ... Langmuir , contains a coating of silver nanoparticles, which ... colleagues note that silver already finds wide use as ...
... tau protein deposits in the brain are characteristic features ... area of the brain that plays a central role ... appears that the toxic effect of tau protein is ... off. Researchers from the Max Planck Research Unit for ...
... Israel,s Wolf Foundation, whose stated mission is "to promote ... named Whitehead Institute Founding Member Rudolf Jaenisch a recipient ... Jaenisch will share this year,s prize with Kyoto University,s ... "their groundbreaking contribution to stem cell research." ...
Cached Biology News:Tau-induced memory loss in Alzheimer's mice is reversible 2Tau-induced memory loss in Alzheimer's mice is reversible 3Whitehead member Rudolf Jaenisch honored for groundbreaking stem cell research 2
(Date:4/16/2015)... , April 16, 2015  RegeneRx Biopharmaceuticals, ... announced its U.S. joint venture with G-treeBNT (ReGenTree ... phase 3 clinical trial for the orphan disorder, ... trial for dry eye syndrome (DES) in the ... eye drops, RGN-259/GBT201, this year.  Each of these ...
(Date:4/16/2015)... PHOENIX, AZ (PRWEB) April 16, 2015 ... and makes it easier for research institutions to learn ... collect clinical data. , The timing is ideal since ... on Tuesday. Research Kit is an open-source framework for ... 9. It provides a way for researchers to collect ...
(Date:4/16/2015)... DIEGO , April 16, 2015 Avelas ... dedicated to improving cancer surgeries, announced today that it ... fluorescent cancer illuminator, AVB-620, in women with primary, non-recurrent ... the company also welcomed the addition of Steven ... The open label, dose escalation study will ...
(Date:4/16/2015)... and MENLO PARK, Calif. , ... (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical company ... new orphan drug indications, today announced that the ... a clinical trial site for the ongoing, multicenter Phase ... multiforme (GBM), the most common and deadly form of ...
Breaking Biology Technology:RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5Infographic Illustrates Potential for Research Kit to Impact Clinical Research 2Infographic Illustrates Potential for Research Kit to Impact Clinical Research 3Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5
... - The University of Wisconsin Medical Foundation ... the Medical Foundation's clinical data and to improve the ... has choosen QDX Platform V Integration Services from ... company based in Englewood, Colorado. , ,The Medical Foundations ...
... Inc. , a provider of single-molecule DNA analysis technology, announced ... deadly type of brain tumor, known as oligodendroglioma. OpGen, based ... Center and professor of genetics and chemistry at the ... Schwartz . , ,Optical mapping, invented by Schwartz, will enable ...
... A few weeks ago, I referred to offshore outsourcing ... rapidly becoming an issue de lannee (an election year ... and increasing questions about the economic future of the ... spectrum from the contenders for the Democratic presidential nomination ...
Cached Biology Technology:UW Medical Foundation Integrates Medical Records 2OpGen joins UW, Henry Ford Heath in Improving Brain Tumor Treatment 2The Great Offshore Outsourcing Debate 2
WIF-1 (N-20)...
Mouse monoclonal [1.T.4] to WAVE 1 ( Abpromise for all tested applications). Antigen: His6 fusion protein corresponding to full-length rat WAVE1. Entrez Gene ID: 8936...
IgG2b, k APC clone A95-1, Isotype Rat IgG2b, kappa, 0.1 mg ....
...
Biology Products: